fam-trastuzumab deruxtecan-nxki
Enhertu Approved for Unresectable or Metastatic HER2-positive Solid Tumors
The FDA granted accelerated approval to fam-trastuzumab Enhertu for adult patients with unresectable or metastatic ...
APRIL 10, 2024
FDA Approves Enhertu to Treat Gastric and GEJ Adenocarcinomas
The FDA approved approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo/AstraZeneca) for adults with ...
JANUARY 31, 2021
Load more